PROTAC-based EZH2 degrader therapy (National University of Singapore)

N/A

Report date: 2023/12/27 18:07:22

Base Information

Drug NamePROTAC-based EZH2 degrader therapy (National University of Singapore)
Drug Alias NameN/A
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 degraders
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational University Of Singapore
China Registration ClassN/A

Develop Information

Active CompaniesNational University Of Singapore
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A